Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Wainberg

Showing results (31-40 of 341) with videos related to

Pageof 35
Sort By:
AIDS (London, England)|March 28, 2003
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?Mike Youle, Mark A Wainberg
Virologie (Montrouge, France)|January 9, 2020
Antiretroviral therapy with integrase inhibitors: more optionsFrançois Raffi, Mark A Wainberg
Retrovirology|November 16, 2013
World AIDS Day: together we will stop HIV transmission and conquer AIDSMark A Wainberg, Andrew Lever
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabinePedro Cahn, Mark A Wainberg
Viruses|August 29, 2014
Is resistance to dolutegravir possible when this drug is used in first-line therapy?Thibault Mesplède, Mark A Wainberg
AIDS Reviews|January 31, 2003
Might the M184V substitution in HIV-1 RT confer clinical benefit?Marco Petrella, Mark A Wainberg
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Resistance issues with new nucleoside/nucleotide backbone optionsMark A Wainberg, Dan Turner
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptaseMatthias Götte, Mark A. Wainberg
Medgenmed : Medscape General Medicine|October 24, 2007
The 16th International Conference on AIDS: will it leave a legacy?Helene Gayle, Mark A Wainberg
Retrovirology|December 21, 2012
Multiple choices for HIV therapy with integrase strand transfer inhibitorsFrancois Raffi, Mark A Wainberg
Pageof 35

Showing results (31-40 of 341) with videos related to

Sort By:
Pageof 35
AIDS (London, England)|March 28, 2003
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?Mike Youle, Mark A Wainberg
Virologie (Montrouge, France)|January 9, 2020
Antiretroviral therapy with integrase inhibitors: more optionsFrançois Raffi, Mark A Wainberg
Retrovirology|November 16, 2013
World AIDS Day: together we will stop HIV transmission and conquer AIDSMark A Wainberg, Andrew Lever
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabinePedro Cahn, Mark A Wainberg
Viruses|August 29, 2014
Is resistance to dolutegravir possible when this drug is used in first-line therapy?Thibault Mesplède, Mark A Wainberg
AIDS Reviews|January 31, 2003
Might the M184V substitution in HIV-1 RT confer clinical benefit?Marco Petrella, Mark A Wainberg
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Resistance issues with new nucleoside/nucleotide backbone optionsMark A Wainberg, Dan Turner
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptaseMatthias Götte, Mark A. Wainberg
Medgenmed : Medscape General Medicine|October 24, 2007
The 16th International Conference on AIDS: will it leave a legacy?Helene Gayle, Mark A Wainberg
Retrovirology|December 21, 2012
Multiple choices for HIV therapy with integrase strand transfer inhibitorsFrancois Raffi, Mark A Wainberg
Pageof 35